Tag: PADN-CFDA

TCT2022| Pulnovo Medical Announced That The Latest Results Of PADN-CFDA Pivotal Trial Indicate Effectiveness And Safety of PADN For The Treatment Of Pulmonary Arterial Hypertension (PAH)

SHANGHAI, Sept. 23, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, today announced the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study on the world’s largest and most influential American transcatheter cardiovascular therapy conference (TCT 2022). […]